Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Nutr Biochem 1997;8:660-672 5
| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) | The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials
Persistent redness, warmth, or pain that lasts more than 48 hours warrants stopping and consulting a clinician
Su frmula se complementa con nutrientes como N-acetil-L-cistena, L-metionina y selenio, compuestos que intervienen en diferentes procesos metablicos y que contribuyen al mantenimiento del equilibrio antioxidante del organismo
3rd Party Test Results
The website information is easy to read and comprehend
US$ 29.06
US$ 20.30
US$ 25.26
US$ 27.16
US$ 26.26
